23种药物与炎症性肠病之间的关联:一个双样本的门德尔随机化研究
Lei He1, Tuo Deng1, Yurong Huang2
1Department of Gastroenterology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
这项研究调查了23种药物,发现免疫抑制剂可以降低炎症性肠病 (IBD) 风险. 糖尿病药物也显示出潜力,而酸和β抑制剂可能会增加IBD风险.
科学领域:
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 炎症性肠病 (IBD) 涉及慢性胃肠道炎症,原因不明.
- 目前IBD的治疗方法侧重于疾病诱导和缓解,需要探索新的治疗方案.
- 门德尔随机化 (MR) 分析是研究药物和疾病之间的因果关系的宝贵工具.
研究的目的:
- 调查23种已批准的药物与发展炎症性肠病 (IBD) 的风险之间的潜在因果关系.
- 探索现有的药物作为IBD预防和管理的潜在治疗选择.
主要方法:
- 使用公开可用的全基因组关联研究 (GWAS) 统计数据进行了两样本的门德尔随机化 (MR) 分析.
- 逆方差加权 (IVW) 方法是主要分析方法,由加权中位数,MR Egger回归和简单/加权模型支持.
- 考克兰的Q统计和MR-Egger测试被用来评估异质性和性.
主要成果:
- 免疫抑制剂与IBD风险呈负因果关联 (OR=0.7389,p=0.0046),也观察到性结肠炎 (UC) 和克罗恩病 (CD).
- 糖尿病药物表明可能降低IBD (OR=0.9266,p=0.0058) 和UC (OR=0.9020,p=0.0046) 的风险.
- 酸和衍生物与IBD风险增加有关 (OR=1.2737,p=0.0345),而β-阻断剂与UC风险增加有关 (OR=1.1893,p=0.0046).
结论:
- 免疫抑制剂可以减轻IBD的风险,在UC和CD亚型中显示一致的效果.
- 糖尿病药物在降低IBD风险方面表现有前途,特别是在UC.
- 酸衍生物和β-阻断剂需要进一步调查,以确定它们是否有可能分别增加IBD和UC风险.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
